TME Pharma N.V. (EPA:ALTME)

France flag France · Delayed Price · Currency is EUR
0.0793
+0.0009 (1.15%)
May 14, 2026, 2:30 PM CET
Market Cap7.46M +19.0%
Revenue (ttm)27.00K
Net Income-4.58M
EPS-0.07
Shares Out94.09M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume92,435
Average Volume379,897
Open0.0792
Previous Close0.0784
Day's Range0.0766 - 0.0793
52-Week Range0.0490 - 0.1480
Beta0.61
RSI56.44
Earnings DateMay 7, 2026

About TME Pharma

TME Pharma N.V., a clinical-stage biopharmaceutical company, focuses on the development of proprietary therapeutics for the treatment of cancer in Germany. The company’s Spiegelmer platform has a proprietary pipeline of clinical-stage product candidates, including its lead cancer drug candidate, NOX-A12, which is under development as a combination therapy for various cancer indications, such as metastatic pancreatic and colorectal cancer, and glioblastoma. It also developing NOX-E36, which has completed Phase 1/2a clinical trial for the treatme... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1997
Employees 12
Stock Exchange Euronext Paris
Ticker Symbol ALTME
Full Company Profile

Financial Performance

Financial Statements